Biotech Values

[DewDiligence]

AdPEDF update:

About 7 minutes were devoted to GNVC's AdPEDF program in AMD at the very end of today’s GNVC CC:

http://biz.yahoo.com/cc/7/37377.html

A phase-2 study AdPEDF study with 50-70 patients is expected to begin as soon as mid-year. I infer that Dr. Campochiaro at Johns Hopkins will likely be the lead investigator as he has been in the phase-1 trial AdPEDF trial now nearing completion.

Something that, to my knowledge, hadn’t been revealed previously is that the phase-1 AdPEDF trial is being conducted at six clinical sites.

Based on today's CC, I think AdPEDF should be moved up a notch on the competitive ladder in AMD.